PDF: CLOTBUST
(2004)Objective
CLOTBUST tested whether continuous transcranial Doppler (TCD) ultrasound enhances IV tPA-mediated recanalization in acute MCA stroke within 3 hours.
Study Summary
• TCD+IV tPA increased early complete recanalization (46% vs 18%)
• No increase in symptomatic ICH with ultrasound
• Trend toward better 90-day outcomes (mRS 0–1: 42% vs 29%)
• No increase in symptomatic ICH with ultrasound
• Trend toward better 90-day outcomes (mRS 0–1: 42% vs 29%)
Intervention
Phase 2, multicenter randomized trial of 2-MHz TCD ultrasound vs sham monitoring after standard IV tPA in patients with MCA occlusion. Continuous insonation lasted 2 hours.
Inclusion Criteria
Acute MCA stroke with residual flow on TCD, NIHSS ≥10, onset <3h, tPA eligible
Study Design
Arms: TCD-enhanced tPA vs tPA + placebo monitoring
Patients per Arm: 63 per group (126 total)
Outcome
• Primary (recanalization or early dramatic recovery): 49% vs 30%, p=0.03
• Sustained complete recanalization at 2h: 38% vs 13%, p=0.002
• Symptomatic ICH: 4.8% in both groups
• Sustained complete recanalization at 2h: 38% vs 13%, p=0.002
• Symptomatic ICH: 4.8% in both groups
Bottom Line
Continuous 2-MHz transcranial Doppler during IV t-PA significantly increased early complete recanalization and the composite of early recanalization or dramatic clinical recovery without increasing symptomatic intracerebral hemorrhage; trends toward better 3-month outcomes were not statistically significant.
Major Points
- CLOTBUST was the first randomized trial of ultrasound-enhanced thrombolysis (sonothrombolysis) — demonstrating that continuous 2-MHz TCD monitoring during IV tPA more than DOUBLED complete recanalization rates (46% vs 18%, p<0.001).
- 126 patients with MCA occlusion confirmed by TCD (TIBI grades 0–3) treated with IV tPA within 3 hours, randomized to continuous 2-MHz TCD monitoring vs sham monitoring for 2 hours.
- Primary combined endpoint (complete recanalization by TIBI criteria OR dramatic clinical recovery within 2 hours) favored active TCD: 49% vs 30% (RR 1.6, 95% CI 1.03–2.6, p=0.03).
- The mechanism: ultrasound energy at 2 MHz enhances tPA-mediated fibrinolysis by mechanically agitating the clot surface, increasing tPA penetration into the thrombus, and promoting acoustic streaming that delivers more drug to the clot interface.
- Safety signal was reassuring: sICH rates identical at 4.8% in both groups — proving that ultrasound augmentation did NOT increase hemorrhagic risk despite dramatically increasing recanalization.
- TIBI (Thrombolysis in Brain Ischemia) flow grading system was developed specifically for this trial: grade 0 (absent), 1 (minimal), 2 (blunted), 3 (dampened), 4 (stenotic), 5 (normal). It became a standard TCD assessment tool for acute stroke.
- 3-month outcomes trended favorably but were not significant (mRS 0–1: 42% vs 29%, p=0.20) — the trial was powered for the surrogate recanalization endpoint, not clinical outcomes, as a phase 2 proof-of-concept study.
- Led to CLOTBUST-ER (2017): operator-independent hands-free headframe device tested in a phase 2 trial. However, the CLOTBUST-ER trial found no significant benefit, possibly due to device limitations and the evolving role of thrombectomy.
- Innovative blinding: sonographers were unblinded (had to operate TCD), but treating physicians and outcome assessors were blinded. Device audio was muted and displays turned away from treating team in both groups.
- Historical importance: CLOTBUST established the proof of concept for sonothrombolysis, but the field was ultimately overtaken by mechanical thrombectomy (MR CLEAN, ESCAPE, etc.) which achieves near-complete recanalization regardless of adjunctive therapies.
Study Design
- Study Type
- Phase 2, multicenter, randomized, placebo-controlled trial with blinded treating physicians
- Randomization
- Yes
- Blinding
- Treating physicians and outcome assessors blinded to group assignment; sonographers unblinded to deliver monitoring; devices’ audio muted and displays turned away from treating team
- Sample Size
- 126
- Follow-up
- 3 months
- Countries
- United States, Spain, Canada
Primary Outcome
Definition: Composite of complete recanalization by TIBI criteria or early/dramatic clinical recovery (NIHSS ≤3 or decrease ≥10 points) within 2 hours after t-PA bolus
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| 30% | 49% | - (RR 1.6; 95% CI 1.03–2.6) | 0.03 |
Limitations & Criticisms
- Phase 2 proof-of-concept with only 126 patients — adequately powered for surrogate recanalization endpoint but NOT for clinical outcomes (mRS at 90 days). The 13% absolute difference in mRS 0–1 would require ~500 patients to confirm.
- Sonographers necessarily unblinded — they had to operate the TCD device. Although treating physicians were blinded, early recanalization assessment by TCD inherently required the unblinded sonographer's involvement.
- Operator-dependent technique requiring skilled TCD sonographers available 24/7 — severely limits real-world implementation. Many stroke centers lack TCD-trained personnel, especially off-hours.
- Baseline imbalance: more control patients treated within 2 hours (43% vs 27%) — earlier treatment favors recanalization, potentially biasing against the treatment group. However, TCD effect remained significant after adjustment.
- The majority of patients enrolled at one dominant center (Houston) — raises external validity concerns about whether results are generalizable to other clinical settings.
- 2-MHz diagnostic frequency used — this is standard diagnostic TCD frequency, but subsequent research explored lower frequencies (microsphere-enhanced, 2-MHz with microbubbles in NOR-SASS) and showed mixed results, leaving optimal ultrasound parameters undefined.
- Did not compare to mechanical thrombectomy — in the modern endovascular era (post-2015), the clinical niche for sonothrombolysis is unclear since thrombectomy achieves ~90% recanalization rates.
- CLOTBUST-ER (2017) follow-up with hands-free operator-independent device was negative — raising questions about whether the original CLOTBUST benefit was partly due to operator expertise or continuous optimization of insonation angle.
- Short 2-hour monitoring window — some re-occlusions occurred after monitoring ceased, potentially underestimating the benefit of sustained ultrasound exposure.
Citation
N Engl J Med. 2004;351(21):2170-2178.